Contact this trialFirst, we need to learn more about you.
PLK-1 Inhibitor
Onvansertib for Small Cell Lung Cancer
Recruiting1 awardPhase 2
Baltimore, Maryland
This trial is testing onvansertib, a drug that blocks an enzyme helping cancer cells grow, in patients with small cell lung cancer who can't use standard chemotherapy. By stopping the cancer cells from repairing themselves, the drug aims to slow down or stop their growth.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service